Lazard Asset Management
ADPT icon

Lazard Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Lazard Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$589K Buy
27,450
+2,352
+9% +$36K ﹤0.01% 1388
2026
Q1 		$348K Buy
25,098
+3,471
+16% +$55.3K ﹤0.01% 1467
2025
Q4 		$351K Sell
21,627
-34,331
-61% -$560K ﹤0.01% 1483
2025
Q3 		$837K Sell
55,958
-6,596
-11% -$80.4K ﹤0.01% 1196
2025
Q2 		$728K Buy
62,554
+32,364
+107% +$294K ﹤0.01% 1392
2025
Q1 		$222K Buy
30,190
+383
+1% +$2.94K ﹤0.01% 1599
2024
Q4 		$177K Buy
+29,807
New +$164K ﹤0.01% 1641
2024
Q2 		– Sell
-175,821
Closed -$564K – 2208
2024
Q1 		$564K Sell
175,821
-15,786
-8% -$61.1K ﹤0.01% 1031
2023
Q4 		$938K Sell
191,607
-7,753
-4% -$35.4K ﹤0.01% 967
2023
Q3 		$1.09M Sell
199,360
-5,927
-3% -$39.2K ﹤0.01% 962
2023
Q2 		$1.38M Sell
205,287
-198
-0.1% -$1.47K ﹤0.01% 941
2023
Q1 		$1.81M Buy
205,485
+897
+0.4% +$7.91K ﹤0.01% 927
2022
Q4 		$1.56M Sell
204,588
-176,229
-46% -$1.37M ﹤0.01% 932
2022
Q3 		$2.71M Buy
380,817
+19,083
+5% +$180K ﹤0.01% 821
2022
Q2 		$2.93M Buy
361,734
+124,864
+53% +$1.1M ﹤0.01% 834
2022
Q1 		$3.29M Sell
236,870
-1,004,636
-81% -$15.8M ﹤0.01% 819
2021
Q4 		$34.8M Buy
1,241,506
+69,230
+6% +$2.12M 0.04% 363
2021
Q3 		$39.8M Buy
1,172,276
+31,222
+3% +$1.13M 0.05% 333
2021
Q2 		$46.6M Buy
1,141,054
+205,040
+22% +$7.97M 0.05% 295
2021
Q1 		$37.7M Buy
936,014
+363,221
+63% +$19.7M 0.05% 317
2020
Q4 		$33.9M Sell
572,793
-173,453
-23% -$8.94M 0.04% 329
2020
Q3 		$36.3M Sell
746,246
-44,768
-6% -$1.88M 0.05% 281
2020
Q2 		$38.3M Buy
791,014
+44,118
+6% +$1.61M 0.06% 226
2020
Q1 		$20.7M Buy
746,896
+660,346
+763% +$18.4M 0.04% 306
2019
Q4 		$2.59M Buy
+86,550
New +$2.49M ﹤0.01% 637

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Lazard Asset Management's ADPT Position: Q2 2026 in Review

Lazard Asset Management increased its Adaptive Biotechnologies (ADPT) stake by 9.4% in Q2 2026, buying an estimated $36K and bringing the position to 27,450 shares worth $589K. The position accounts for ﹤0.01% of the portfolio, ranked #1388.

Lazard Asset Management first reported a position in ADPT in Q4 2019 and has held it in 25 quarters since. The position peaked at $46.6M in Q2 2021. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Lazard Asset Management held 27,450 shares of Adaptive Biotechnologies worth $589K as of Q2 2026.
  • Lazard Asset Management bought 2,352 Adaptive Biotechnologies shares in Q2 2026, an estimated $36K.
  • Adaptive Biotechnologies made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1388 holding.
  • Lazard Asset Management first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 25 quarters since.
  • Lazard Asset Management's Adaptive Biotechnologies position peaked at $46.6M in Q2 2021.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.